# Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients

> **NCT06883136** · — · ENROLLING_BY_INVITATION · sponsor: **Qianfoshan Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine

## Key facts

- **NCT ID:** NCT06883136
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-03-12
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-06-29
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06883136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06883136, "Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06883136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*